Serum microRNA expression levels in Turkish patients with Parkinson’s disease
Objective: To determine the serum expression levels of miR-19a, miR-19b, miR-29a, miR-29c, miR-181, miR-195 and miR-221 in Turkish patients with Parkinson's disease (PD) and to…PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results
Objective: Evaluate efficacy and safety of prasinezumab following 52 weeks of treatment in participants with early Parkinson’s disease (PD). Background: Prasinezumab is a humanized monoclonal…A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in De Novo vs Rollover Patients With Parkinson’s Disease: Interim Results
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL-130277; APL) for on-demand treatment of “OFF” episodes in de novo (DN) vs…Rapid on-time onset and sustained improvements in motor states throughout the day following treatment with levodopa/carbidopa intestinal gel (LCIG) vs immediate-release levodopa/carbidopa oral capsules (LCIR)
Objective: To assess the speed of on-time onset and characterize the patterns of motor states throughout the day in advanced Parkinson’s disease patients treated with…A Patient with Gait Disturbance Caused by Parkinson’s Disease: A Case Report
Objective: It is well known that mental simulation of movement in the brain can facilitate motor rehabilitation. Our hypothesis is: can a direct, sequential stimulation…The UP study – Ursodeoxycholic acid (UDCA) as neuroprotective treatment for Parkinson’s disease
Objective: To determine the safety and tolerability of ursodeoxycholic acid (UDCA) in Parkinson’s disease (PD) and explore its neuroprotective potential. Background: We previously undertook the…Effects of Nabilone on non-motor symptoms of Parkinson´s Disease: A randomised placebo-controlled study (The NMS-Nab Study)
Objective: To investigate the effects of the synthetic cannabinoid nabilone for the treatment of non-motor symptoms in Parkinson´s disease (PD) in a controlled fashion. Background:…Real Time Quality Control for Subjective Endpoints in Clinical Trials
Objective: Here we present a system which is capable of performing nearly-real time monitoring of UPDRS part-3 motor assessments using a combination of multidimensional statistics…Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics
Objective: Describe the study design of Part 2 of the MOVES-PD trial (NCT02906020), and report patient characteristics. Background: Mutations in the glucocerebrosidase (GBA) gene are…Types of Pain in Parkinson`s Disease Patients
Objective: To present the characteristics of four different types of pain in Parkinson`s disease (PD) patients. Background: Neurodegeneration can cause a nociceptive disturbances at many…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.